X0609 4 2026-07-01 0000907654 Oruka Therapeutics, Inc. ORKA 0002075401 Sandler Laura Lee false C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100 MENLO PARK CA 94025 0 1 0 0 Chief Operating Officer 1 Common Stock 2026-07-01 4 M 0 5000 7.8 A 241384 D Common Stock 2026-07-01 4 S 0 2237 93.8457 D 239147 D Common Stock 2026-07-01 4 S 0 2263 94.7458 D 236884 D Common Stock 2026-07-01 4 S 0 500 95.472 D 236384 D Employee Warrant (right to buy) 7.80 2026-07-01 4 M 0 5000 0 D 2034-07-14 Common Stock 5000 79996 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.29 to $94.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.38 to $95.19, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.40 to $95.51, inclusive. The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. /s/ Paul Quinlan, as attorney-in-fact for Laura Sandler 2026-07-01